SCHEMBL20122744

SCHEMBL20122744

Cc1nccc2c3cc(Cl)cc(-c4ccc(N5CCN(C)CC5)nc4)c3n(CC3CC3)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 8/20 0.42
ALK Q9UM73 4/20 0.40
TDO2 P48775 1/20 0.39
MET P08581 2/20 0.38
SRC P12931 2/20 0.38
FLT3 P36888 2/20 0.38
AURKB Q96GD4 2/20 0.38
AURKA O14965 1/20 0.38
KIT P10721 1/20 0.38
PDGFRA P16234 1/20 0.38
AXL P30530 1/20 0.38
KDR P35968 1/20 0.38
TYRO3 Q06418 1/20 0.38
DDR1 Q08345 1/20 0.38
MERTK Q12866 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
TNKS O95271 1/20 0.37
HDAC1 Q13547 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20122737 0.93 RET (0.40) RETHDAC1HDAC6CNR2MAPK14
SCHEMBL20122939 0.81 PIK3CA (0.38) RETHDAC1HDAC6JAK2DYRK1A
SCHEMBL30664235 0.81 HDAC1 (0.35) AXLTYRO3MERTKHDAC1HDAC6
SCHEMBL20122880 0.81 HDAC1 (0.35) AXLTYRO3MERTKHDAC1HDAC6
SCHEMBL30664292 0.80 BRD4 (0.37) HDAC1HDAC6ABL1DYRK1A
SCHEMBL20122937 0.80 BRD4 (0.37) HDAC1HDAC6ABL1DYRK1A
SCHEMBL30664339 0.79 CNR2 (0.52) RETTDO2CNR2
SCHEMBL20122978 0.79 CNR2 (0.52) RETTDO2CNR2
SCHEMBL30664227 0.79 DYRK1A (0.45) HDAC1HDAC6DYRK1A
SCHEMBL20122960 0.79 DYRK1A (0.45) HDAC1HDAC6DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2023-11-28 US disclosed
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders SANOFI (FR) 2021-09-28 US disclosed
EP-3792262-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2021-03-17 EP disclosed
EP-3535263-B1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI SA (FR) 2020-09-30 EP disclosed
EP-3318563-A1 SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS SANOFI (FR) 2018-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11827633-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 RET 2243/4885ALK 1421/4885TDO2 89/4885
US-11130755-B2 Substituted pyrido[3,4-b]indoles for the treatment of cartilage disorders COL2A1, IDO1, COL1A1 RET 2243/4885ALK 1421/4885TDO2 89/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.